CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer

Author(s): Hui Zeng, Liling Tang

Journal Name: Current Cancer Drug Targets

Volume 14 , Issue 7 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Cysteine-rich motor neuron1 protein (CRIM1), a novel antagonist of bone morphogenetic proteins (BMPs), is reported to regulate the processing of BMPs preprotein into mature protein and the delivery of BMPs to the cell surface. Previous studies have shown that CRIM1 is an important player in regulating placental development, organogenesis, angiogenesis and kidney disease. Here, we propose that CRIM1 is a potential risk factor in cancer progression and metastasis. The epithelial-mesenchymal transition (EMT), which is characterized by the loss of epithelial phenotype and the acquisition of mesenchymal characteristics, is closely associated with invasion and metastasis of tumors. At the same time, it is hard for us to ignore the importance of angiogenesis in the genesis and progression of cancer. In this review we summarized the construction and previous researches of CRIM1. Furthermore, as it may be involved in tumor development and progression through its potential role in the EMT, capillary formation and angiogenesis maintenance, we proposed for the first time that CRIM1 may be a cancer related factor.

Keywords: Antagonist, angiogenesis, BMPs, cancer treatment targets, CRIM1, EMT.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [652 - 658]
Pages: 7
DOI: 10.2174/1568009614666140725094125
Price: $65

Article Metrics

PDF: 39